The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.
Berg will use its Interrogative Biology platform in order to assess potential biomarkers of seasonal influenza vaccination outcomes.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.
Sanofi recruits one of AstraZeneca's top scientists to bolster its biotech presence, Reuters reports.
The collaboration will focus on identifying new signaling pathways and targets involved in coronary artery disease.
The study used a modified version of Myriad RBM's DiscoveryMAP immunoassay panel to measure levels of 237 proteins in blood samples from 8,401 patients.
The pharma firm joins Pfizer Canada and AstraZeneca in the National Access Project, which tests tumors for mutations to match patients with potential therapies.
The two methods could shorten the detection time by eliminating the need to amplify the virus with in vitro cell culture.
The data show that RG-012 can enhance the effect of Sanofi's kidney protectant ramipril and suggest the microRNA drug might have use in other chronic kidney diseases.
A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.
A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.
Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.
In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.